Superior Vena Caval Obstruction (SVCO) - Management and Outcome

Phase 1

Completed

• Conditions: Superior Vena Cava Syndrome

• Registration Number: NCT00259584
• Lead Sponsor: University Health Network, Toronto

Brief Summary

All patients with symptomatic malignant SVCO deemed suitable for treatment either with radiation therapy or by stenting will be eligible. They will receive whichever treatment is deemed most clinically appropriate. Symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-10
• Study First Submitted: 2005-11-28
• Study First Submitted QC: 2005-11-28
• Study First Posted: 2005-11-29
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Status Verified: 2010-08
• Last Update Submitted: 2010-08-12
• Last Update Posted: 2010-08-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Symptomatic clinical and radiological diagnosis of superior vena caval obstruction.
• Underlying histological diagnosis deemed appropriate for palliative radiotherapy as treatment by investigator. Patients with chemosensitive tumours such as small cell lung cancer (both untreated and recurrent), lymphoma and testicular tumours, will be eligible if radiation is deemed to be appropriate treatment.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Improvement in an index symptom at 4 weeks as recorded by a daily symptom diary

Secondary Outcome Measures

Name	Time	Method
Time to onset of palliation
Duration of symptom control
Survival
Number of days spent in hospital
Requirement for further treatment

Trial Locations

Locations (1)

University Health Network; 🇨🇦 Toronto, Ontario, Canada